Opthea Advances nAMD Treatment with Sozinibercept

Opthea Limited Sponsored ADR (OPT) has released an update.

Opthea Limited Sponsored ADR is making strides in the treatment of neovascular age-related macular degeneration (nAMD) by focusing on the VEGF-C and -D pathways. At the EURetina Symposium 2024, the company highlighted sozinibercept, a novel anti-VEGF-C & -D inhibitor, as an emerging therapy with the potential to set a new standard in visual outcomes. Despite the evolution of treatments targeting the VEGF pathway, there remains a significant portion of patients with suboptimal responses, indicating a strong need for innovative solutions like sozinibercept.

For further insights into OPT stock, check out TipRanks’ Stock Analysis page.